Skip to content

    Recently Viewed

      Listening...

      Home / Media Center / Press releases / Pharmaceuticals /
      Janssen Licenses Diabetes Research Programs From Evotec and Harvard University

      Janssen Licenses Diabetes Research Programs From Evotec and Harvard University

      Share Article
      share to

      RARITAN, NJ (JULY 10, 2012) — Janssen Pharmaceuticals, Inc. (Janssen) announced today it has licensed exclusive access to a portfolio of small molecule and biologic research programs focused on the regeneration of insulin-producing beta cells in people with diabetes from Evotec AG and Harvard University. All drug development on behalf of Janssen will be conducted by Janssen Research & Development, LLC.

      In 2011, Evotec, Harvard and the Howard Hughes Medical Institute (HHMI) formed a collaboration called CureBeta to further analyze and characterize drug candidates and targets identified by scientists at the Harvard University laboratory of Douglas Melton, Ph.D. Dr. Melton is the Thomas Dudley Cabot Professor at Harvard University and an HHMI Investigator.

      “Beta cell survival and function play a critical role in maintaining normal glucose levels and when they are compromised, can contribute to the onset of diabetes,” said Peter DiBattiste, M.D., Global Therapeutic Head, Cardiovascular and Metabolism at Janssen Research & Development. “This collaboration strengthens our long term diabetes development pipeline and directly reflects our commitment to making a difference for the millions of people worldwide living with this disease.”

      One of the hallmarks of both type 1 and type 2 diabetes is the decline of functional beta cells. Beta cells located in the pancreatic islet synthesize, store and secrete insulin. Their progressive failure and loss leads to diabetes, which makes the beta cell an important target for both type 1 and type 2 diabetes research.

      About Janssen Pharmaceuticals, Inc. and Janssen Research & Development, LLC
      At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop and bring innovative products, services and solutions to people throughout the world. Janssen Pharmaceuticals, Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

      For more information on Janssen Pharmaceuticals, Inc., visit us at www.janssenpharmaceuticalsinc.com or follow us on Twitter at www.twitter.com/JanssenUS.

      For more information on Janssen Research & Development, LLC, visit us at http://janssenrnd.com/.

      ###

      Media contacts:
      Ernie Knewitz
      Phone: (908) 927-2953
      eknewitz@its.jnj.com

      Christina Chan
      Phone: (908) 927-5769
      cchan20@its.jnj.com

      Investor contacts:
      Stan Panasewicz
      Phone: (732) 524-2524

      Louise Mehrotra
      Phone: (732) 524-6491

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.